Viatris deal-related expenses drag Biocon's Q3 net into Rs 42 cr loss

This, even as revenues rise 36% and Ebitda is up 35%

Bangalore based biotech firm Biocon has posted a 25 per cent year on year dip in net profit before exceptional items to Rs 140 crore for the third quarter of 2022-23 fiscal, while its Ebitda grew 35 per cent.

Net of tax and minority interest, the exceptional items amount to Rs 182 crore, resulting in a net loss of Rs 42 crore for Q3FY23. Its revenues, however, posted robust growth of 36 per cent to Rs 3,020 crore, and the Ebitda was up 35 per cent to Rs 723 crore. Net R&D expense for the quarter was up 144 per